Trials / Completed
CompletedNCT00876070
Community Oncology Setting Cost Analysis and Disease Outcomes of Taxane Use in Metastatic Breast Cancer
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 198 (actual)
- Sponsor
- SCRI Development Innovations, LLC · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a retrospective medical record abstraction study. It is a review and evaluation of up to 300 metastatic breast cancer patients treated with Abraxane or other taxanes such as paclitaxel and docetaxel to determine the overall cost of care for Abraxane compared to other taxanes in the first-line metastatic cancer setting and the cost of care for Abraxane compared to other taxanes when broken down by individual components of cost. In addition, the investigators will review the following patient outcomes: response rate, duration of therapy, toxicity, and survival.
Conditions
Timeline
- Start date
- 2008-11-01
- Primary completion
- 2009-11-01
- Completion
- 2011-02-01
- First posted
- 2009-04-06
- Last updated
- 2011-11-21
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00876070. Inclusion in this directory is not an endorsement.